Our Most Recent Episode
Dr. Sarah Holstein, MD, PhD, Roswell Park Cancer Institute Interview Date: September 19, 2014 Summary Dr. Sarah Holstein describes a very exciting new immunotherapy that will open in a Phase I/II clinical trial shortly. This new drug called ALT-803 by Altor Bioscience was listed as one of the most exciting immunotherapy choices according to the […]
Calling All Musicians: New Music Contest to Support Myeloma Research!
We are announcing a new contest called Songs for Life to help raise funds for multiple myeloma research. Here’s how it works:
Our Next Episode
Our Next Show: Using vaccines as the ultimate personalized medicine in myeloma with Dr. Larry Kwak, MD, PhD
Friday, September 26, 8 am PDT, 9 am MDT, 10 am CDT, 11 am EDT
Call In by Phone to Listen Live: (347) 637-2631 or
Join us as we hear Dr. Larry Kwak describe the ultimate in personalized medicine by using vaccines in blood cancers. He will share his award-winning work in lymphoma and how that success is being used in myeloma today. Dr. Kwak’s laboratory studies ways of using immunotherapies to target myeloma and uses vaccines that can be combined with the unique cells of a patient’s own system to kill myeloma. Through his innovative vaccine work, he was recognized in 2010 in the Time 100, those named by Time magazine as one of the most 100 influential persons in the world.
Dr. Larry Kwak, MD, PhD is Professor in the Department of Lymphoma/Myeloma, in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center. He is also Chairman of the Department of Lymphoma/Myeloma, Associate Director in the Center for Cancer Immunology Research and Justin Distinguished Endowed Chair in Leukemia research at MD Anderson. Dr. Kwak leads a large lab at MD Anderson focused on immunotherapy work including vaccines and has received numerous awards including the Faculty Achievement Award in Clinical Research, the Team Science Award for the International Society for the Biological Therapy of Cancer, and awards from the American Society for Clinical Investigation, the NCI for Technology Transfer, and Time magazine’s top 100 in 2010.
Our Previous Episodes
Extending Outcomes with Continuous Myeloma Maintenance: Dr. Antonio Palumbo, MD, University of Torino
Detecting myeloma relapse early - The new Hevylite® test can help with Dr. Stephen Harding of The Binding Site
What's new in MGUS? Very interesting ASCO findings and the diagnostics you need to have as an MGUS patient with Dr. Brendan Weiss, MD
The hopeful discovery of an engineered measles virus for myeloma treatment with Dr. Stephen Russell, MD, PhD
Where are we headed with new agents and transplant approaches in myeloma? Dr. Paul Richardson, MD, Dana-Farber Cancer Institute
A compelling European approach in myeloma care: Collaboration, Referrals and Established Guidelines with Dr. Pieter Sonneveld, MD, PhD, Erasmus MC
Myeloma is not a single disease: The illuminating discovery and implications for care with Dr. Michael Kuehl, MD, PhD of the NCI
Dr. Michael Shapira, MD shares an early vaccine for myeloma and his work to raise the age ceiling for allo and auto transplants
Dr. Sergio Giralt of Memorial Sloan-Kettering discusses the role of transplant, how transplant side effects (including host vs. graft) are being minimized and how all roads to a cure lead through complete remission
Dr. Craig Crews of the Crews Laboratory at Yale University describes his discovery and development of carfilzomib (Kyprolis) and what it takes to get a new drug across the "Valley of Death"
Our Next Show: How does a drug begin as an idea and become an actual myeloma therapy in the clinic? Dr. Craig Crews, Crews Laboratory at Yale University discusses his discovery and development of carfilzomib (Kyprolis)
Dr. Bensinger discusses a wide variety of new approaches to treatment including monoclonal antibody studies, new oral proteasome inhibitor studies, combinations with and without transplants, and the pros and cons of allo vs. auto transplantation
Dr. Benson describes how immunotherapy and NK cells work, and why most cancers are genetic or molecular diseases and not anatomical diseases
Three myeloma themes with Dr. Robert Z. Orlowski of MD Anderson Cancer Center:Immunotherapy, making transplant better and using new small molecules for more convenient myeloma care
Dr. Leif Bergsagel, MD of the Mayo Clinic shares the impact of the MYC translocation in myeloma progression and relapse and a new target that boosts immunity while impacting myeloma cells
Genes that drive myeloma growth and why new discoveries of myeloma's complexities are hopeful with Dr. Jens Lohr, MD of The Broad Institute and Dana Farber Cancer Institute
Dr. Philip McCarthy of Roswell Park Cancer Institute on transplants: best induction therapies, best approaches for high risk and how patients can recover faster
Dr. Damian Green shares a new approach to combine two proven approaches (immunotherapy and radiation) to selectively target only active myeloma cells using the common CD38 protein
Who should consider a donor (allo) transplant? Young, high-risk myeloma patients and patients with high relapse risk. Considering clinical trials as your first treatment option with Dr. Parmeswaran Hari.
Shutting down myeloma growth by changing the soil where it grows with Dr. Noopur Raje of Massachusetts General Hospital Cancer Center
What can you do when your myeloma medication is no longer working? Dr. Jatin Shah describes the best new approaches to overcome drug resistance and a host of treatment alternatives.
Find a multiple myeloma specialist near you. We’ve moved this directory to the www.myelomacrowd.org site.